Drug intelligence / Profile preview

salbutamol + theophylline (Square Pharmaceuticals)

Development stage
Unknown
Lead developer
Square Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Duasma is an oral combination therapy consisting of salbutamol and theophylline, designed for the management of bronchospasm in respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Salbutamol is a short-acting beta-2 adrenergic receptor agonist that induces rapid bronchodilation by relaxing airway smooth muscle through the activation of adenylate cyclase and subsequent increase in intracellular cyclic AMP. Theophylline, a methylxanthine derivative, complements this action by non-selectively inhibiting phosphodiesterase (PDE) enzymes, which further prevents the breakdown of cyclic AMP, and by acting as a competitive antagonist at adenosine receptors. Together, these components provide both immediate and sustained relief of airway obstruction, reducing the work of breathing and improving pulmonary function in patients with reversible obstructive airway diseases.

Brand names
Duasma
Other names
albuterol + theophylline
02

Targets

ADORA2B (Adenosine A2B receptor)ADORA3 (Adenosine A3 receptor)PDE3ADORA2A (Adenosine A₂A Receptor)ADRB1 (β1)ADORA1 (Adenosine receptor A1 subtype)PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on salbutamol + theophylline (Square Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on salbutamol + theophylline (Square Pharmaceuticals).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call